View More Recent Stories

Sep 4, 2024 05:06AM Ascendis Pharma (ASND) PT Lowered to $180 at Goldman Sachs
Sep 4, 2024 04:57AM Ascendis Pharma (ASND) PT Lowered to $178 at Citi
Sep 3, 2024 05:15PM Ascendis Pharma (ASND) Misses Q2 EPS by 55c; cuts Skytrofa revenue outlook
Sep 3, 2024 05:07PM Ascendis Pharma (ASND) and Royalty Pharma (RPRX) Enter $150M Royalty Funding Agreement
Aug 21, 2024 06:21AM Ascendis Pharma (ASND) PT Raised to $174 at JPMorgan
Aug 12, 2024 01:43PM Ascendis Pharma (ASND) PT Raised to $195 at Goldman Sachs
Aug 12, 2024 07:00AM Ascendis Pharma (ASND): FDA Approves YORVIPATH (Palopegteriparatide) as the First and Only Treatment for Hypoparathyroidism in Adults
Aug 12, 2024 06:57AM Ascendis Pharma (ASND) Halted, News Pending
Jun 25, 2024 05:36AM TD Cowen Upgrades Ascendis Pharma (ASND) to Buy
Jun 13, 2024 05:55PM Ascendant Resources Announces Results of Annual General Meeting of Shareholders
Jun 13, 2024 05:55PM Ascendant Resources Announces Results of Annual General Meeting of Shareholders
Jun 13, 2024 05:55PM Ascendant Resources Announces Results of Annual General Meeting of Shareholders
Jun 12, 2024 05:58AM BofA Securities Reiterates Buy Rating on Ascendis Pharma (ASND)
View More Recent Stories